Nightstar Therapeutics plc ("
Nightstar") is
pleased to announce that, at the General Meeting and the Court
Meeting held earlier today in connection with the recommended
acquisition of the entire issued and to be issued share capital of
Nightstar by Tungsten Bidco Limited, a newly-incorporated company
and wholly-owned indirect subsidiary of Biogen Inc., all
resolutions proposed were passed by the requisite majorities and
accordingly the Scheme was approved. Details of the resolutions
passed are set out in the notices of General Meeting and Court
Meeting at pages ix to xiii and vi to viii respectively of the
combined circular and proxy statement dated 9 April 2019 (the
"
Scheme Document").
The detailed voting results in relation to the
General Meeting and Court Meeting are set out below.
Unless otherwise defined herein, capitalised
terms and expressions used in this announcement shall have the
meanings given to them in the Scheme Document.
Effective Date and
Timetable
The outcome of the General Meeting and Court
Meeting means that Conditions A(i) and (ii) (as set out in Part III
of the Scheme Document) have been satisfied. The Scheme remains
subject to sanction by the Court at the Court Hearing, which is to
take place on 6 June 2019, and the delivery of a copy of the Court
Order to the Registrar of Companies. Nightstar expects that the
Scheme will become effective on 7 June 2019.
Voting Results of the General
Meeting
The table below sets out the results of the poll
at the General Meeting. Each Nightstar Shareholder, present in
person or by proxy, was entitled to one vote per Nightstar Share
held at the Scheme Voting Record Time, provided that holders of the
Nightstar Shares proposed to be re-designated as Deferred Shares
were not entitled to vote on the Ordinary Resolution or the Scheme
Special Resolution.
|
FOR |
AGAINST |
TOTAL |
WITHHELD* |
Resolution |
No. ofvotes |
% ofVotes |
No. ofVotes |
% ofVotes |
No. ofVotes |
No. ofVotes |
To authorise the Nightstar Board to re-designate certain Nightstar
Shares as Deferred Shares |
26,352,023 |
99.98 |
% |
4,845 |
0.02 |
% |
26,356,868 |
30,711 |
To approve the terms of each of the Buy-Back Agreements
("Ordinary Resolution") |
26,341,802 |
99.98 |
% |
4,865 |
0.02 |
% |
26,346,667 |
30,591 |
To authorise the Nightstar Board to take all such action as they
consider appropriate to carry the Scheme into the effect, including
by amending Nightstar’s articles of association ("Scheme
Special Resolution") |
26,371,902 |
99.98 |
% |
4,665 |
0.02 |
% |
26,376,567 |
691 |
* A vote withheld is not a vote in law and,
accordingly, is not counted in the calculation of the proportion of
votes "For" nor "Against" the Resolutions.
The total number of Nightstar Shares in issue at
the Scheme Voting Record time was 33,536,215. As at the Scheme
Voting Record Time, Nightstar held no Shares in treasury.
Therefore, the total voting rights in Nightstar as at the Scheme
Voting Record Time were 33,536,215.
Voting Results of the Court
Meeting
The table below sets out the results of the poll
at the Court Meeting. Each Nightstar Scheme Shareholder, present in
person or by proxy, was entitled to one vote per Nightstar Scheme
Share held at the Scheme Voting Record Time.
|
Number ofNightstar Scheme Shares voted |
Percentage ofNightstar SchemeShares voted |
Number ofNightstar Scheme Shareholderswho
voted |
Percentage ofNightstar Scheme Shareholderswho
voted |
Number of Nightstar Scheme Shares voted as a percentage of
issued ordinary share capital entitled to vote on the
Scheme |
FOR |
26,371,982 |
100 |
% |
6 |
100 |
% |
78.8 |
% |
AGAINST |
0 |
0 |
% |
0 |
0 |
% |
0 |
% |
TOTAL |
26,371,982 |
100 |
% |
6 |
100 |
% |
78.8 |
% |
Enquiries:
Nightstar
Investor Information |
investors@nightstartx.com |
|
|
Media Enquiries |
media@nightstartx.com |
|
|
Information |
info@nightstartx.com |
Centerview Partners (Financial adviser
to Nightstar)
Alan Hartman |
+1 212 380 2665 |
|
|
Andrew Rymer |
+1 212 429 2349 |
|
|
James Hartop |
+44 (0)20 7409 9730 |
Finsbury (PR adviser to
Nightstar)
Kal Goldberg |
+1 646 805 2005 |
|
|
Chris Ryall |
+1 646 306 0747 |
Important notices relating to financial
advisers
Centerview Partners UK LLP ("Centerview
Partners"), which is authorised and regulated by the FCA,
is acting exclusively for Nightstar and no one else in connection
with the matters referred to in this announcement. Centerview
Partners is not and will not be responsible to anyone other than
Nightstar for providing the protections afforded to its clients or
for providing advice in connection with the contents of this
announcement or any matter referred to in this announcement.
The City Code on Takeovers and
Mergers
The City Code on Takeovers and Mergers does not
apply to the Acquisition.
Overseas shareholders
The release, publication or distribution of this
announcement in jurisdictions other than the United Kingdom and the
United States may be restricted by law and therefore any persons
who are subject to the laws of any jurisdiction other than the
United Kingdom or the United States (including Restricted
Jurisdictions) should inform themselves about, and observe, any
applicable legal or regulatory requirements. Any failure to comply
with applicable legal or regulatory requirements of any
jurisdiction may constitute a violation of securities laws in that
jurisdiction. This announcement has been prepared for the purpose
of complying with English law and the information disclosed may not
be the same as that which would have been disclosed if this
announcement had been prepared in accordance with the laws of
jurisdictions outside England.
Copies of this announcement and any formal
documentation relating to the Acquisition are not being, and must
not be, directly or indirectly, mailed or otherwise forwarded,
distributed or sent in or into or from any Restricted Jurisdiction
or any jurisdiction where to do so would constitute a violation of
the laws of such jurisdiction and persons receiving such documents
(including custodians, nominees and trustees) must not mail or
otherwise forward, distribute or send them in or into or from any
Restricted Jurisdiction. Doing so may render invalid any related
purported vote in respect of acceptance of the Acquisition.
If the Acquisition is implemented by way of an
Offer, the Offer may not (unless otherwise permitted by applicable
law and regulation) be made, directly or indirectly, in or into or
by use of the mails or any other means or instrumentality
(including, without limitation, facsimile, e-mail or other
electronic transmission, telex or telephone) of interstate or
foreign commerce of, or any facility of a national, state or other
securities exchange of any Restricted Jurisdiction and the
Acquisition will not be capable of acceptance by any such use,
means, instrumentality or facilities or from within any Restricted
Jurisdiction.
Further details in relation to Nightstar
Shareholders in overseas jurisdictions are contained in the Scheme
Document.
Notice to U.S. investors in
Nightstar
The Acquisition relates to the shares of a U.K.
company and is being made by means of a scheme of arrangement
provided for under Part 26 of the Companies Act 2006 and subject to
the proxy solicitation rules under the U.S. Exchange Act. The
Acquisition, implemented by way of a scheme of arrangement, is not
subject to the tender offer rules under the U.S. Exchange Act. If,
in the future, Bidder exercises its right to implement the
Acquisition by way of an Offer, subject to the terms of the
Implementation Agreement, the Acquisition will be made in
compliance with applicable U.S. laws and regulations.
It may be difficult for U.S. Nightstar
Shareholders and Nightstar ADS Holders to enforce their rights and
any claim arising out of the U.S. federal securities laws, because
Nightstar is located in a non-U.S. country, and some or all of its
officers and directors are residents of a non-U.S. country. U.S.
Nightstar Shareholders and Nightstar ADS Holders may not be able to
sue a non-U.S. company or its officers or directors in a non-U.S.
court for violations of the U.S. securities laws. Further, it may
be difficult to compel a non-U.S. company and its affiliates to
subject themselves to a U.S. court's judgment.
U.S. Nightstar Shareholders and Nightstar ADS
Holders are urged to consult with legal, tax and financial advisers
in connection with making a decision regarding the Acquisition.
Warning Concerning Forward-Looking
Statements
All statements included in this announcement,
other than statements or characterisations of historical fact, are
forward-looking statements within the meaning of the federal
securities laws, including Section 21E of the U.S. Exchange Act,
and other securities laws. Whenever Nightstar uses words such as
"believe", "expect", "anticipate", "intend", "plan", "estimate",
"will", "may", "predict", "could", "seek", "forecast" and negatives
or derivatives of these or similar expressions, they are making
forward-looking statements. Examples of such forward-looking
statements include, but are not limited to, references to the
anticipated benefits of the Acquisition and the expected time of
effectiveness of the Acquisition. These forward-looking statements
are based upon Nightstar's present intent, beliefs or expectations,
but forward-looking statements are not guaranteed to occur and may
not occur.
Nightstar Shareholders are cautioned that any
forward-looking statements are not guarantees of future performance
and may involve significant risks and uncertainties, and that
actual results may vary materially from those in the
forward-looking statements. Important risk factors that may cause
Nightstar's actual results to differ materially from their
forward-looking statements include, but are not limited to: (1) the
Acquisition is subject to the satisfaction or waiver of certain
conditions, including the sanction of the Scheme by the Court,
which conditions may not be satisfied or waived; (2) uncertainties
as to the timing of the consummation of the Acquisition and the
ability of each party to consummate the Acquisition; (3) the risk
that the Acquisition disrupts the parties' current operations or
affects their ability to retain or recruit key employees; (4) the
possible diversion of management time on Acquisition-related
issues; (5) litigation relating to the Acquisition; (6) unexpected
costs, charges or expenses resulting from the Acquisition; and (7)
potential adverse reactions or changes to business relationships
resulting from the announcement or completion of the
Acquisition.
The information contained in Nightstar's filings
with SEC, including in Nightstar's Form 10-K, as amended by Form
10-K/A, for the year ended 31 December 2018, identifies other
important factors that could cause actual results to differ
materially from those stated in or implied by the forward-looking
statements in this announcement. Nightstar's filings with the SEC
are available on the SEC's website at www.sec.gov. You should not
place undue reliance upon forward-looking statements. Except as
required by law, Nightstar does not intend to update or change any
forward-looking statements as a result of new information, future
events or otherwise.
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Mar 2025 to Apr 2025
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Apr 2024 to Apr 2025